Sunday, February 03, 2008

FDA Warnings Did Not Herald Closer Pediatric SSRI Supervision or Drastic Drop in Prescribing

FDA Warnings Did Not Herald Closer Pediatric SSRI Supervision or Drastic Drop in Prescribing

Marlene Busko

January 17, 2008 — Following US Food and Drug Administration (FDA) warnings about pediatric suicidality risk with selective serotonin-reuptake inhibitors (SSRIs), patient monitoring did not increase and prescribing dipped modestly, according to 2 studies.

The first study, which looked at provider contact following initial antidepressant prescribing, is published in the January issue of the American Journal of Psychiatry. The second study, which examines trends in prescribing antidepressants, appears in the January issue of Archives of General Psychiatry.

 

1 comment:

Truthman30 said...

SSRI’s like Paxil (Seroxat) are extremely dangerous , Bob Fiddaman is a Seroxat patient campaigner and he has been blogging about the Seroxat scandal for some years. Recently GSK (manufacturers of Seroxat – GlaxoSmithKline) have used threatening and intimidating tactics to try and suppress his voice.

I am calling all mental health campaigners to highlight this on their blogs if they can.

http://fiddaman.blogspot.com/2008/03/gsk-lawyers-target-seroxat-campaigner.html